Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 10

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 10
---
 $3,302,674  
    $3,647,026  
    $963,855 

    SUPPLEMENTAL CASH FLOW INFORMATION: 

    Cash and cash equivalents 
    $3,227,918  
    $3,567,270  
    $963,855 
  
    Restricted cash 
     74,756  
     79,756  
     - 
  
    Cash, restricted cash and cash equivalents 
    $3,302,674  
    $3,647,026  
    $963,855 

    NON-CASH FINANCING ACTIVITIES: 

    Issuance of common shares to Keystone Capital LLC for equity line of credit 
    $-  
    $250,000  
    $- 
  
    Issuance of common shares to Arena Investors LP for equity line of credit 
    $-  
    $500,000  
    $- 
  
    Conversion of Series A, Series B and Series C Preferred Stock to common stock 
    $2,074,340  
    $-  
    $- 
  
    Reclassification of deferred offering costs to additional paid-in capital 
    $112,232  
    $-  
    $- 
  
    Reclassification of accrued expenses to accounts payable 
    $1,143,826  
    $-  
    $- 
  
    Issuance of Series D preferred stock for investment in equity securities 
    $500,000  
    $-  
    $- 

See
accompanying notes to the condensed consolidated financial statements

5

CERO THERAPEUTICS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2025

(Unaudited)

NOTE
1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS

Nature
of Operations – CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) (“CERo”, “Successor” or the “Company”),
F/K/A Phoenix Biotech Acquisition Corp. (“PBAX”) was incorporated in Delaware on June 8, 2021. PBAX was formed for the purpose
of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with
one or more businesses (a “business combination”).

The
Company is an